Mark Boyar is a well-respected longtime value investor, he publishes a research-intensive newsletter and has an excellent record over many decades. He first mentioned the stocks that he talked about last time he presented, at the Las Vegas iteration of this Congress back in May (we covered that here) — he did well with Dole […]
Articles
- Most Relevant
- Most Recent
As I type this I’m waiting for the deliveryman to arrive, bringing my new router and computer — one thing I can say about life as the Stock Gumshoe, it’s hell on my laptop. The poor thing is so clogged with spam and has been sent on so many forced marches across the internet as […]
Immupharma: blockbuster potential?Just recently I’ve taken a long position in Immupharma and am quite excited about the potential. One of the fellow members on a BB had posted a very well researched and balanced article that I would like to share. So, with courtesy of Sicilian_kan [cheers!]: ”(last updated on 26 April 2016: Disclaimer – no information […]
This microblog is not for a discussion of stocks – it’s for telling fellow Gummies and Gummie-esses about WEB SITES THAT HAVE SOMETHING TO DO WITH INVESTING that you find useful. To start with, http://www.macrotrends.net/ has 60 historical charts ranging from topics like …..A Gold to Oil Ratio Historical Chart ….tracks the ratio of the […]
There was big news from one of my personal holdings this week, and it’s also a stock that I’ve suggested twice to the Irregulars and written about several times over the years so I thought it warranted at least a little reaction … particularly because it drove the shares down precipitously. So I’ve bought more […]
This is the third time I’ve bought an IPO on its first day of trading, and the second time I’ve bought exposure to a SPAC over the past year — hopefully it will work out as well as the others. I saw Chamath Palihapitiya speak at the Delivering Alpha conference on Tuesday, along with Starwood’s […]
[Ed. note: Today we have another article from Jim Skelton, the Blind Squirrel, who is sharing his experiences as a financial advisor with us. He has agreed to our trading restrictions, the opinions he expresses are his own, and we haven’t reviewed, approved or screened his ideas. His previous articles can be seen here.] Hello, fellow […]
I’ve been meaning to check in on one of the few mutual funds that I’ve written in detail about for you, so in the absence of any other big portfolio moves we’ll take a minute for that today. DoubleLine Shiller Enhanced CAPE (DSEEX) is a “better mousetrap” kind of fund, which should make us start […]
Happy holiday season, campers! What’s up with the Real Money Portfolio as we head into a slow Thanksgiving week? The most brutal takedown of the week was NVIDIA (NVDA), which I’m sure many of you noticed this morning — that’s a stock that hit a stop loss a while back for us (I was watching […]
Every year we resolve to do better, right? That’s the human condition — we are frail, weak, and conflicted… we are busy, irritable, and unfocused… and we want to do better. It’s no different for your friends here at Stock Gumshoe… so today, as we recover from the Ides of March, I offer up some […]
It’s the end of the year, so we’re running into all those stories again about how this is the longest expansion in history, and we have never gone this long without seeing a 20% (or more) drop in the market. Which, of course, fires up the market timer in all of us — especially now […]
Have you been watching what’s going on with the trendy pot stocks lately? Holy crap. This reminds me now of 1999 more than it reminds me of the cryptocurrency bubble of this past winter — these larger marijuana companies, like many of the dot com companies (and unlike most cryptos, of course), are real businesses […]
Today I’m breaking up our Friday File into two segments, which many of you have noted that you prefer — one part is a teaser pitch solution, the other is an update on a few stocks that I own and/or have suggested to the Irregulars. The teaser pitch is a look into Cabot’s “Stock of […]
The ides of February are dismal and dreary here in the wet and grey Pioneer Valley of Massachusetts, but we remain hopeful of the sunshine to come. What do I have to share with you, dear Irregulars, as we seek a little brightness to end the week? Well, I do have a few buys to […]
I watched the Grant’s Interest Rate Observer Conference this week via webcast, and it continues to be one of my favorite events — though I’d rather be there in person. These are some of my notes about the presentations I found most interesting… no “quick take” here, sorry, these are mostly notes and my responses. […]
Things will be a little quiet here at Stock Gumshoe for the next week or so — I’m off to do my big fundraising ride for Dana-Farber tomorrow, and will then be taking several days off to recuperate next week and spend time with family… I’ll be back with the Friday File next week, but […]
2017 was a year of tremendous accomplishment for Clean Teq Holdings in every respect. We saw remarkable achievements in mine construction, in finance, and in market development, with landmark contracts in every business segment; We saw a complex business appear as if by magic, including business offices on four continents, and the launch of business […]
[Ed. Note: Dr. KSS writes about medicine biotech stocks for the Gumshoe Irregulars. He chooses his own topics, and his words and opinions are his own. Visit his Stock Gumshoe page for his past articles and most recent comments.] Assessing biotechnology stocks involves use of lots of mental microscopes and magnifying lenses. But the task […]
Anyone know what penny stock Ray Blanco talks about?
Ed. note: Today we’re experimenting with adding some more voices to the world of Stock Gumshoe to add a different perspective and cover some sectors in more detail. We’ve asked longtime reader Myron Martin, who spends a lot of time with junior mining stocks and other small caps, to share his perspective with you — […]
I’ve got a whole passel of things to comment on for you today — I want to update my thoughts on some insurance company stocks that I own and that I touted as beneficiaries of a big switch in the insurance market over the past year or so, check in on a buy and a […]
[ed note: This is the latest in a series of articles from medical writer “Doc Gumshoe” (who, yes, is not actually a doctor) — it’s on the hot topic if antibiotic resistance, and we’ll likely continue to see companies touted and teased that aim to either fight resistant bacteria or clean up hospitals to slow […]
Well, if you see a teaser pitch for Canadian Edge you know, at least, that the stocks being teased are, well, Canadian. So that helps us out — it means we can hopefully put just a couple litres of fuel into our Thinkolateur and we ought to be well on our way to some nice, […]
I don’t normally look at shares in companies so small listed in the famed arena of the ”pump and dump” stock promoters but this is one I stumbled across by accident while researching HEV/EV’s and renewable energy generally. I found an author, John Petersen, on Seeking Alpha who writes quite a bit about energy storage […]
[ed note: Doc Gumshoe is our favorite medical writer, and he usually pops in to explore a topic or answer questions readers have posed a couple times a month — he’s not a medical doctor and, as always, his opinions are his own.] Let’s start this off with a hypothetical case, or rather, three hypothetical […]
The Winklevoss twins came to talk to talk about Bitcoin. Which is definitely the least typical presentation I’ve seen at the Value Investing Congress — these are my notes from the talk. Bitcoin is a math-based asset created over a decentralized peer to peer network. They are hoping to convince us that Bitcoin will be […]
Mark Boyar is a well-respected longtime value investor, he publishes a research-intensive newsletter and has an excellent record over many decades. He first mentioned the stocks that he talked about last time he presented, at the Las Vegas iteration of this Congress back in May (we covered that here) — he did well with Dole […]
Guy Gottfried has a nice, albeit short, record of choosing excellent little Canadian value stocks that have risen in value pretty substantially over the year or so following his presentation. Of course, that doesn’t mean his pick this year will jump right up — but he’s presenting before the market opens, and the 500 or […]
No big stock “reveal” today, but perhaps our blatheration will be of some interest anyway. We’ve had a number of readers write in asking about a heavily promoted trading service called Passive Income Trader — this is a service that’s been around for a year or two, as far as I can tell, and they’ve […]
The folks at Wall Street Daily are very active in trying to build up their subscriber lists — and Louis Basenese, who writes the WSD Insider newsletter as well as the more small-cap focused MicroCap Tech Trader, has made a couple of hot picks over the last year or so that have gone up abruptly […]
DISCLAIMER: I am long shares of SBOTF and may add to the position at any time. ”Even blind squirrels find an acorn every now and then” OK, I know .. there is already plenty of discussion re Stellar Biotechnologies (SBOTF) on the site. Since Travis posted the tease from Nick Hodge in early July, the […]
[Ed. note: Michael Jorrin, who we like to call “Doc Gumshoe,” is not a doctor, he is a longtime medical writer who contributes pieces for us that we hope give a good background or perspective on medical issues (and marketing) for those of us who are as overwhelmed with “live to 150” promises as we […]
Ed. note: Here is another installment from longtime reader Myron Martin. Myron has agreed to our trading restrictions (he won’t trade the stocks he mentions for three days), but we have not reviewed, approved or screened his stocks or ideas, and the opinions he expresses are solely his own. Myron’s past commentaries can be seen […]
I’ve been seeing a new ad from Amber Mason for the DailyWealth Trader service in the last week or so — it’s all about a special way to earn dividends, but to do so much more quickly. What’s she talking about? Well, I expect we’ll find that this is yet another option-selling pitch (several of […]
[ed. note: We’ve been privileged to share with you some “non investment” commentary here from Michael Jorrin, a longtime medical writer who we like to call “Doc Gumshoe” — today he’s got a new piece for us that should help us think skeptically about yet more of the “easy solution” promises people make about health, […]
Shah Gilani has a new pitch going around for his Capital Wave Forecast, all about how the short-selling and manipulation by the six big bullion-trading banks brought the “flash crash” in gold and drove it lower … but will certainly drive it higher now that the move is done, with his expected price of $2,500 […]
“One unique type of gold investment (that most Americans have never heard of) based in British Columbia has outperformed every asset class in existence – rising twice as fast as gold. “The average investor in this gold secret made over 80% a year for 20 straight years – even after gold crashed last year. “But […]
Does the Supreme Court decision announced June 17th, giving the FDA the right to sue pharmaceutical companies that enter into “pay to delay” agreements with generic drug makers represent a blow to big pharma, a gift to the generic sector, and a boon to consumers? I don’t think so, and here’s why: The situations where […]
The Foolies are out in force with another ad for their flagship Stock Advisor newsletter, we’re on vacation this week so I’m not putting together brand new articles but I reminded you about their “#1 Stock Across the Motley Fool Universe” yesterday … and today we’ll remind you about the other pick they’re pitching in […]
Your friendly neighborhood Gumshoe is on vacation this week and celebrating Independence Day, but we’ve gotten so many questions about this pick that we can’t resist sharing it with you. Again. The Motley Fool has hyped up this same pick several times this year — quite profitably so far, though I’ve not been along for […]